Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL127825 | 0.79 | ALDH1A1 (0.38) | — | |
| SCHEMBL533387 | 0.79 | — | — | |
| SCHEMBL746326 | 0.76 | — | — | |
| SCHEMBL2478085 | 0.76 | — | — | |
| SCHEMBL12274056 | 0.76 | CYP11B1 (0.34) | — | |
| SCHEMBL37909 | 0.71 | — | — | |
| SCHEMBL229872 | 0.71 | — | — | |
| SCHEMBL5610595 | 0.71 | CFTR (0.35) | — | |
| SCHEMBL743045 | 0.69 | APP (0.31) | — | |
| SCHEMBL9205769 | 0.69 | LNPEP (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117836296-A | Pyrazolopyridone compounds | 百济神州有限公司 | 2024-04-05 | — | — | CN | claimed |
| US-20230416205-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | TENVIE THERAPEUTICS, INC. | 2023-12-28 | — | — | US | claimed |
| EP-4247376-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Denali Therapeutics Inc. (US) | 2023-09-27 | — | — | EP | claimed |
| CN-116507608-A | Compounds, compositions, and methods | 戴纳立制药公司 | 2023-07-28 | — | — | CN | claimed |
| WO-2022109268-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2022-05-27 | — | — | WO | claimed |
| US-20210371417-A1 | AZAINDOLE COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2021-12-02 | — | — | US | claimed |
| EP-3634962-A1 | AZAINDOLE COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | Global Blood Therapeutics, Inc. (US) | 2020-04-15 | — | — | EP | claimed |
| CN-110997671-A | Azaindole compounds as histone methyltransferase inhibitors | 全球血液疗法股份有限公司 | 2020-04-10 | — | — | CN | claimed |
| US-20180354947-A1 | AZAINDOLE COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2018-12-13 | — | — | US | claimed |
| WO-2018226998-A1 | AZAINDOLE COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2018-12-13 | — | — | WO | claimed |
| US-20120196863-A1 | 1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | SIENA BIOTECH S.P.A. (IT) | 2012-08-02 | — | — | US | claimed |
| US-20120190852-A1 | MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA | UBE INDUSTRIES, LTD. (JP) | 2012-07-26 | — | — | US | claimed |
| EP-2415763-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA | Ube Industries, Ltd. (JP) | 2012-02-08 | — | — | EP | claimed |
| US-20110054172-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | UBE CORPORATION (JP) | 2011-03-03 | — | — | US | claimed |
| EP-2264009-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | Ube Industries, Ltd. (JP) | 2010-12-22 | — | — | EP | claimed |
| US-7504412-B2 | Imidazopyridine derivatives | BANYU PHARMACEUTICALS, CO., LTD. (JP) | 2009-03-17 | — | — | US | claimed |
| US-20080200494-A1 | Imidazopyridine Derivatives | MSD K.K. (JP) | 2008-08-21 | — | — | US | claimed |
| US-20070299070-A1 | 2-Arylcarboxamide-Nitrogenous Heterocycle Compound | MSD K.K. (JP) | 2007-12-27 | — | — | US | claimed |
| EP-1798221-A1 | 2-ARYLCARBOXAMIDE-NITROGENEOUS HETEROCYCLE COMPOUND | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-06-20 | — | — | EP | claimed |
| EP-1657242-A1 | IMIDAZOPYRIDINE DERIVATIVES | Banyu Pharmaceutical Co., Ltd. (JP) | 2006-05-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196863-A1 | 1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | BACE2, BACE1, PSEN1 | DAO 1973/4885 |
| US-20080200494-A1 | Imidazopyridine Derivatives | MC1R, MC3R, MC5R | DAO 1564/4885 |
| US-20210371417-A1 | AZAINDOLE COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | EHMT2, EHMT1, EZH2 | DAO 2488/4885 |
| US-20230416205-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | NLRP3, NLRP1, NOD1 | DAO 3653/4885 |
| US-20070299070-A1 | 2-Arylcarboxamide-Nitrogenous Heterocycle Compound | MCHR2, MCHR1, NPY2R | DAO 669/4885 |
| US-20180354947-A1 | AZAINDOLE COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | EHMT2, EHMT1, EZH2 | DAO 2488/4885 |
| US-20110054172-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | PTGER2, PTGER1, PTGDR2 | DAO 358/4885 |
| US-20120190852-A1 | MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA | F12, C1S, AKR1C3 | DAO 543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.